Difference between revisions of "British-American Tobacco"
m (Text replacement - "|twitter= " to "") |
(Covid "vaccine" from plants) |
||
| Line 9: | Line 9: | ||
|subgroups=Tekel, Bentoel Group, Souza Cruz, Niemeyer | |subgroups=Tekel, Bentoel Group, Souza Cruz, Niemeyer | ||
}} | }} | ||
| + | '''British-American Tobacco''' (BAT) has been part of many deep state activities over the years. | ||
| + | |||
| + | |||
| + | ==Covid "vaccines"== | ||
| + | In December 2022, BAT's US Bio-tech arm, [[Kentucky BioProcessing]] (KBP) announced plans to commence a Phase I first-time-in-human study of its [[COVID-19]] vaccine candidate. According to the press release, the candidate vaccine has been developed using KBP's innovative fast-growing plant-based technology. This unique approach has a number of possible advantages, including the rapid production of the vaccine's active ingredients in around 6-weeks, compared to several months using conventional methods. The candidate vaccine also has the potential to be stable at room temperature. If successful, the speed of production of the active ingredients has the potential to reduce the time between identifying new viruses and strains, and vaccine development and deployment to those who need it.<ref>https://www.bat.com/media/press-releases/_2020/december/dec-16---bat-progresses-covid-19-candidate-vaccine-into-phase-i- [https://archive.is/wip/TFSOs archived]</ref> | ||
| + | |||
| + | |||
| + | |||
| + | |||
| + | |||
{{SMWDocs}} | {{SMWDocs}} | ||
==References== | ==References== | ||
{{reflist}} | {{reflist}} | ||
{{Stub}} | {{Stub}} | ||
Latest revision as of 00:04, 9 November 2024
 British-American Tobacco  (Company)     | |
|---|---|
 | |
| Headquarters | London, United Kingdom |
| Subgroups | • Tekel • Bentoel Group • Souza Cruz • Niemeyer |
British-American Tobacco (BAT) has been part of many deep state activities over the years.
Covid "vaccines"
In December 2022, BAT's US Bio-tech arm, Kentucky BioProcessing (KBP) announced plans to commence a Phase I first-time-in-human study of its COVID-19 vaccine candidate. According to the press release, the candidate vaccine has been developed using KBP's innovative fast-growing plant-based technology. This unique approach has a number of possible advantages, including the rapid production of the vaccine's active ingredients in around 6-weeks, compared to several months using conventional methods. The candidate vaccine also has the potential to be stable at room temperature. If successful, the speed of production of the active ingredients has the potential to reduce the time between identifying new viruses and strains, and vaccine development and deployment to those who need it.[1]
Employee on Wikispooks
| Employee | Job | Appointed | End |
|---|---|---|---|
| Peter Macadam | Chairman | 1976 | 1982 |
